Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus

S G West, Sterling G. West, S C Johnson, STEVEN C. JOHNSON
Annals of internal medicine · 1988 · vol. 108(5) , pp. 703–706 · doi:10.7326/0003-4819-108-5-703 · PMID:3358571 · W2065859996
Non-randomised trial OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This noncontrolled trial found that danazol therapy normalized platelet counts in six patients with systemic lupus erythematosus and severe autoimmune thrombocytopenia refractory to other treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

STUDY OBJECTIVE: to determine the efficacy of danazol therapy in patients with systemic lupus erythematosus with severe autoimmune thrombocytopenia refractory to other therapies. DESIGN: noncontrolled clinical trial, with a minimum of 8 weeks of therapy, the maximum determined by clinical response. SETTING: referral-based rheumatology clinic at an army medical center. PATIENTS: sequential sample of six patients with systemic lupus erythematosus with severe autoimmune thrombocytopenia refractory to high-dose glucocorticoids. Four patients also failed splenectomy, or cytotoxic drugs, or both. INTERVENTIONS: danazol, 200 mg four times per day, was added to the previous therapeutic regimen for at least 2 months. MEASUREMENTS AND MAIN RESULTS: all six patients had normal platelet counts within 6 weeks of starting danazol treatment. After resolution of thrombocytopenia for at least 1 month, immunosuppressive medications were tapered; one patient had a relapse. During an average follow-up of 12 months, the danazol dose was lowered in the five remaining patients but could not be discontinued without recurrence of thrombocytopenia. During danazol therapy, platelet-bound IgG antibodies and circulating immune complexes did not decrease significantly. Danazol was well tolerated. CONCLUSIONS: danazol appears to be a useful adjunctive treatment for refractory autoimmune thrombocytopenia associated with systemic lupus erythematosus.

My notes (saved in your browser only)

MeSH descriptors

Autoimmune Diseases Danazol Lupus Erythematosus, Systemic Pregnadienes Thrombocytopenia Adult Aged Antigen-Antibody Complex Antigen-Antibody Complex Autoimmune Diseases Autoimmune Diseases Azathioprine Azathioprine Blood Platelets Blood Platelets Combined Modality Therapy Danazol Drug Resistance Drug Therapy, Combination Female

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (4)

References (14)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-10T11:01:05.103053+00:00
pubmed
last seen: 2026-10-08T21:30:01.769541+00:00
License: CC0 · commercial use OK